Comparative Pharmacology
Head-to-head clinical analysis: DANTRIUM versus ROBAXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANTRIUM versus ROBAXIN.
DANTRIUM vs ROBAXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dantrolene inhibits calcium release from the sarcoplasmic reticulum by binding to the ryanodine receptor (RyR1), thereby reducing intracellular calcium concentration and decreasing muscle contraction.
Centrally acting muscle relaxant; depresses polysynaptic reflexes at spinal cord and supraspinal levels, possibly via glycine receptor agonism and GABAergic modulation.
Initially 25 mg orally once daily for 7 days, then 25 mg three times daily for 7 days, then 50 mg three times daily for 7 days, then 100 mg three times daily; maximum 400 mg/day in divided doses. For malignant hyperthermia crisis: IV bolus 1 mg/kg, repeated as needed up to 10 mg/kg cumulative dose.
1500 mg orally 4 times daily, or 750 mg orally every 4 hours as needed. Maximum 6 g/day. For IV use: 1 g (10 mL) as a single intravenous injection or infusion.
None Documented
None Documented
Terminal elimination half-life: 8.7-14.4 hours in adults; longer with hepatic dysfunction.
1-2 hours in adults; clinically, multiple daily dosing required to maintain effect.
Renal: ~65% as unchanged drug; biliary/fecal: ~15% as metabolites; remainder metabolized and eliminated via urine.
Renal excretion of metabolites accounts for 99% of elimination; <1% excreted as unchanged drug in urine.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant